Zymeworks (ZYME) Intangibles (2021 - 2026)
Zymeworks (ZYME) posted Intangibles of $1.2 million for Q1 2026, down 13.04% sequentially from $1.3 million in Q4 2025, and down 65.08% YoY from $3.4 million in Q1 2025.
Analysis
Zymeworks (ZYME) Intangibles (2021 - 2026) Analysis & Trends
Zymeworks has reported Intangibles for 6 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Intangibles fell 65.08% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 65.08% YoY) and the FY2025 annual result came in at $1.3 million, down 70.5% from the prior year.
- Intangibles slipped to $1.2 million in Q1 2026 per ZYME's latest filing, from $1.3 million in the prior quarter.
- Over five years, Intangibles peaked at $17.6 million in Q4 2022 and troughed at $341000.0 in Q2 2024.
- A 5-year average of $6.4 million and a median of $6.4 million in 2024 frame the typical range for Intangibles.
- The sharpest annual moves came in 2024 and 2025: Intangibles sank 95.39% in 2024, then jumped 499.71% in 2025.
- Over 5 years, Intangibles stood at $17.6 million in 2022, then sank by 56.57% to $7.7 million in 2023, then sank by 40.23% to $4.6 million in 2024, then plunged by 70.5% to $1.3 million in 2025, then declined by 13.04% to $1.2 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $1.2 million, $1.3 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 63.28 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 60.96 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 998,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 998,000.00 |
| Mar 31, 2026 | 1.17 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 4.58 Mn |
| Sep 30, 2024 | 6.41 Mn |
| Jun 30, 2024 | 7.11 Mn |
| Mar 31, 2024 | 17.63 Mn |
| Dec 31, 2023 | 17.63 Mn |
| Sep 30, 2023 | 17.63 Mn |
| Jun 30, 2023 | 17.63 Mn |
| Mar 31, 2023 | 17.63 Mn |
| Dec 31, 2022 | 17.63 Mn |
| Sep 30, 2022 | 17.63 Mn |
| Dec 31, 2021 | 17.63 Mn |